Krsnaa Diagnostics Limited

Krsnaa Diagnostics Allots ₹430 Crore NCDs to Asian Development Bank

Krsnaa Diagnostics Limited has approved the allotment of 43,000 Non-Convertible Debentures worth ₹430 crore to Asian Development Bank on a private placement basis. These NCDs carry a 7.790% annual interest and have a tenure of 7 years, with redemption starting six months post-allotment.

Krsnaa Diagnostics Re-appoints Rajendra Mutha as Executive Chairman for 5 Years

Krsnaa Diagnostics Limited's Board has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a five-year term, effective April 26, 2026. This decision is subject to shareholder approval. Mr. Mutha has over two decades of experience in the diagnostics sector.

Krsnaa Diagnostics Re-appoints Rajendra Mutha as Executive Chairman for 5 Years

Krsnaa Diagnostics Limited's Board approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a five-year term, effective April 26, 2026. This decision requires shareholder approval via postal ballot. Mr. Mutha has over two decades of experience in the diagnostics sector.

Krsnaa Diagnostics: Q3 FY26 Earnings Call Transcript Released

Krsnaa Diagnostics released its Q3 FY26 earnings call transcript. Revenue was ₹1,812 million (approx. 181.2 crore), up 4% YoY. The company recovered over ₹130 crore in government receivables. Normalized EBITDA was ₹474 million (approx. 47.4 crore) with a 26% margin, and normalized PAT was ₹168 million (approx. 16.8 crore) with a 9% margin. The B2C segment saw 8x YoY revenue growth.

Krsnaa Diagnostics to Meet Investors/Analysts on Feb 13

Krsnaa Diagnostics Limited will hold a one-on-one physical meeting with Akash Ganga Limited on February 13, 2026, in Mumbai. Discussions will be based on publicly available information only.

Krsnaa Diagnostics publishes unaudited financial results for Q3 FY26

Krsnaa Diagnostics Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were published in newspapers on February 7, 2026, and will be available on the company's investor website.

Krsnaa Diagnostics Releases Audio Recording of Q3 FY26 Earnings Call

Krsnaa Diagnostics Limited has released the audio recording of its earnings call for the quarter and nine months ended December 31, 2025. The call took place on February 06, 2026. The recording is available on the company's website.

Krsnaa Diagnostics Q3 FY26: Revenue Up 4% to ₹1,812 Crore, PAT at ₹168 Crore

Krsnaa Diagnostics reported Q3 FY26 consolidated revenue of ₹1,812 crore, up 4% YoY. Normalised PAT was ₹168 crore. For 9M FY26, revenue grew 9% to ₹5,802 crore, and PAT increased 5% to ₹597 crore. The company is expanding its network with over 200 CT/MRI centers planned and launched its first Apulki Healthcare Hospital.

Krsnaa Diagnostics Updates Key Managerial Personnel List

Krsnaa Diagnostics Limited has updated its list of Key Managerial Personnel (KMPs) for materiality assessments and disclosures. The list includes Managing Director Mr. Yash Mutha and Group CEO Mr. Mitesh Dave. This information is available on the company's website and was submitted to stock exchanges on February 5, 2026.

Krsnaa Diagnostics Q3 FY26 Revenue Up 4% YoY to ₹181.2 Crore, PAT Declines 21%

Krsnaa Diagnostics reported Q3 FY26 revenue of ₹181.2 crore, up 4% YoY. Nine-month revenue reached ₹580.2 crore, up 9% YoY. PAT for Q3 FY26 declined 21% YoY to ₹15.2 crore. The company recovered over ₹130 crore in government receivables. Apulki Healthcare launched its first hospital, a 150-bed cancer and cardiac facility in Pune.

Krsnaa Diagnostics Q3 FY26 Results: Profit Before Tax ₹212 Cr Standalone, ₹197 Cr Consolidated

Krsnaa Diagnostics reported unaudited standalone results for Q3 FY26 with revenue from operations at ₹1,594.32 crore and profit before tax at ₹212.22 crore. Consolidated revenue from operations was ₹1,812.01 crore with profit before tax at ₹197.66 crore. The company is addressing a tax demand of ₹513.86 million.

Krsnaa Diagnostics Q3FY26 Results: Revenue ₹5,179 Cr (Standalone), ₹5,801 Cr (Consolidated)

Krsnaa Diagnostics reported standalone revenue of ₹5,179.29 crore and consolidated revenue of ₹5,801.70 crore for the nine months ended December 31, 2025. Profit before tax was ₹781.89 crore (standalone) and ₹786.66 crore (consolidated). The company is contesting a ₹513.86 crore tax demand related to past assessment years.

Krsnaa Diagnostics Schedules Q3FY26 Earnings Conference Call for Feb 6, 2026

Krsnaa Diagnostics Limited will hold its Q3FY26 earnings conference call on February 6, 2026, at 12:30 PM IST. Management will discuss results for the quarter and nine months ended December 31, 2025. Speakers include Rajendra Mutha and Yash Mutha.

Krsnaa Diagnostics to Meet Investors/Analysts on Feb 10, 2026

Krsnaa Diagnostics Limited officials will meet investors and analysts on February 10, 2026, in Mumbai. The meeting with Systematix Group will be a physical group interaction. Discussions will be limited to publicly available information.

Krsnaa Diagnostics CFO Pawan Daga Resigns; Last Day Jan 19, 2026

Mr. Pawan Daga, Chief Financial Officer of Krsnaa Diagnostics Limited, has resigned. His last working day will be January 19, 2026. The company cited personal and professional priorities as the reason for his departure and acknowledged his five-year tenure.

Krsnaa Diagnostics: Statutory Auditors Convert to LLP

Krsnaa Diagnostics Limited's statutory auditors, M S K A & Associates, have converted into a Limited Liability Partnership (LLP). The firm's name has changed to M S K A & Associates LLP, effective January 12, 2026.

Krsnaa Diagnostics to Meet Investors/Analysts on Jan 8, 2026

Krsnaa Diagnostics Limited will hold a one-on-one virtual meeting with Generational Capital on January 8, 2026, at 13:00 IST onwards. Discussions will be limited to publicly available information, with no unpublished price sensitive information to be disclosed.

Krsnaa Diagnostics to Meet First Water Capital on Jan 8

Krsnaa Diagnostics Limited will conduct a one-on-one physical meeting with First Water Capital on January 08, 2026, in Mumbai. Discussions will be limited to publicly available information.

Krsnaa Diagnostics files SEBI Reg 74(5) certificate for Q3 FY26

Krsnaa Diagnostics Limited submitted its SEBI Regulation 74(5) confirmation certificate for the quarter ended December 31, 2025. The certificate, issued by KFin Technologies, confirms the furnishing of securities dematerialization/rematerialization details to stock exchanges.

Krsnaa Diagnostics to Meet Investors/Analysts on Jan 5

Krsnaa Diagnostics Limited officials will hold a virtual one-on-one investor meeting on January 5, 2026, with NV Capital. Discussions will be limited to publicly available information, with no unpublished price sensitive information to be disclosed. The schedule is subject to change.

Krsnaa Diagnostics to Meet NV Alpha Fund on Dec 29, 2025

Krsnaa Diagnostics Limited will hold a virtual one-on-one meeting with NV Alpha Fund on December 29, 2025. Discussions will be limited to publicly available information.

Krsnaa Diagnostics: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results

Krsnaa Diagnostics Limited will close its trading window from January 01, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter and nine months ending December 31, 2025. This restriction applies to directors, key personnel, and promoters.

Krsnaa Diagnostics Board Approves ₹430 Crore NCD Issuance

Krsnaa Diagnostics' Board approved the issuance of up to ₹430 crore in Unlisted, Secured, Redeemable Non-Convertible Debentures. The NCDs will have a 7-year tenure and will be redeemed in 13 equal installments starting 6 months post-allotment. The issuance is on a private placement basis.

Krsnaa Diagnostics Approves Issuance of Unlisted NCDs Worth ₹430 Crore

Krsnaa Diagnostics Limited's Board approved the issuance of Unlisted, Secured, Redeemable NCDs worth up to ₹430 crore via private placement. The debentures have a 7-year tenure and will be redeemed in 13 installments starting six months post-allotment. Security will be created over company assets.

Krsnaa Diagnostics: Trading Window Closure

Krsnaa Diagnostics announces trading window closure from December 10, 2025, until 48 hours after the board meeting on December 12, 2025, to consider NCD issuance.

Krsnaa Diagnostics notifies about Analyst/Institutional Investor Meeting

Krsnaa Diagnostics will be meeting with Siddhant Partners on December 4, 2025, for a virtual one-on-one interaction. The discussion will be based on publicly available information.

Krsnaa Diagnostics to meet with Athena Investments on 27 Nov 2025

Krsnaa Diagnostics will meet Athena Investments in Mumbai on 27 November 2025 for a one-on-one physical interaction. Discussions will be based on publicly available information.

Krsnaa Diagnostics notifies Analyst/Institutional Investor Meeting

Krsnaa Diagnostics will meet with Nuvama AIF virtually on 20 November 2025 for a one-on-one interaction. Discussions will be based on publicly available information.

Krsnaa Diagnostics Reports Strong Q2 FY26 Results, Plans Major Rajasthan PPP Expansion

Krsnaa Diagnostics reported strong Q2 FY26 results with 11% revenue growth and 18% EBITDA growth. The company is rapidly expanding its Rajasthan PPP project and retail business, expecting significant future revenue accretion.

Audio Recording of Earnings Call for Quarter Ended September 30, 2025

Krsnaa Diagnostics announces the availability of the audio recording of its earnings call for the quarter ended September 30, 2025, held on November 10, 2025.

Newspaper Publication of Unaudited Financial Results for Quarter Ended September 30, 2025

Krsnaa Diagnostics published a newspaper advertisement on November 9, 2025, regarding unaudited financial results for the quarter and half year ended September 30, 2025, in Financial Express and Loksatta.

Krsnaa Diagnostics Reports All-Time High Quarterly PAT and Strong Revenue Growth for Q2 FY26

Krsnaa Diagnostics reported record Q2 FY26 PAT of ₹23.9 crore, up 22% Y-o-Y, with revenue growing 11%. Retail business surged 60% Q-o-Q, driven by network expansion and strong margins.

Krsnaa Diagnostics Announces Highest-Ever Quarterly Profit in Q2 FY26

Krsnaa Diagnostics reports record quarterly profit with revenue at ₹2,060 million, EBITDA at ₹602 million, and PAT at ₹239 million. The company received ACR accreditation and was recognized as India's Most Trusted Diagnostic Brand.

Krsnaa Diagnostics Board Approves Q2 & H1 FY26 Results; Reports Growth Amidst Tax Appeal

Krsnaa Diagnostics approved Q2 and H1 FY26 standalone and consolidated financial results, reporting revenue and profit growth. Company appeals ₹51.39 crore Income Tax demand, expecting no material impact.

Krsnaa Diagnostics reports strong Q2 and H1 FY26 financial performance; addresses tax demand

Krsnaa Diagnostics announced robust Q2 and H1 FY26 financial results with increased revenue and profit, alongside an update on a tax demand which management believes will not have a material impact.

Krsnaa Diagnostics Announces Investor Conference Call on November 10, 2025

Krsnaa Diagnostics Limited announces a conference call to discuss the results for the quarter and half-year ended September 30, 2025, scheduled for November 10, 2025, at 10:00 Hrs (IST).

Newspaper Advertisement Regarding Investor Awareness

Krsnaa Diagnostics published newspaper advertisements on October 16, 2025, to inform shareholders under the 'Saksham Niveshak' initiative, in line with IEPFA and MCA guidelines. The ads appeared in Financial Express and Loksatta.

Krsnaa Diagnostics to meet High-Net-Worth Individuals in Pune on October 7, 2025

Krsnaa Diagnostics will meet High-Net-Worth Individuals in Pune on October 7, 2025, for a one-on-one interaction based on publicly available information.

Submission of Certificate under SEBI Regulations for Quarter Ended September 30, 2025

Krsnaa Diagnostics Limited submits certificate under SEBI Regulations for quarter ended September 30, 2025, confirming securities dematerialization/rematerialization details were furnished to stock exchanges.

Krsnaa Diagnostics to meet with Analysts/Institutional Investors

Krsnaa Diagnostics approves continuation of Chetan Desai as Non-Executive Director

Krsnaa Diagnostics Holds 15th Annual General Meeting on 25 September 2025

Corrigendum to Notice of 15th AGM: Clarification on Secretarial Auditor Appointment

Krsnaa Diagnostics to meet with Arihant Capital Group on September 23, 2025

Krsnaa Diagnostics to meet with Sanlam Limited and Haitong securities on Sept 8, 2025

Krsnaa Diagnostics to hold 15th AGM on September 25, 2025

Newspaper Publication for 15th Annual General Meeting

Krsnaa Diagnostics to meet with Elara Capital on September 03, 2025

Krsnaa Diagnostics Q1 FY26: Rajasthan Award & Retail Growth Drive Performance

Krsnaa Diagnostics Reports Strong Q1 FY26 Results, Recommends ₹2.75 Final Dividend